Evidence map›Paper›PMID 36304472›Full record

ArticleFrontiers in immunology2022

Identification and verification of the prognostic value of CUL7 in colon adenocarcinoma.

Chengxing Wang, Zhenyu Zhao, Yuhao Zhang, Weijun Liang, Chaorong Zhou, Weixing Lin, Yu He, Meimei Wu, Zijie Meng, Yuehua Liao and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Chengxing WangDepartment of Gastrointestinal Surgery, Jiangmen Central Hospital, Jiangmen, China.
Zhenyu ZhaoThe First Affiliated Hospital, Jinan University, Guangzhou, China.
Yuhao ZhangDepartment of Gastrointestinal Surgery, Jiangmen Central Hospital, Jiangmen, China.
Weijun LiangDepartment of Gastrointestinal Surgery, Jiangmen Central Hospital, Jiangmen, China.
Chaorong ZhouDepartment of Gastrointestinal Surgery, Jiangmen Central Hospital, Jiangmen, China.
Weixing LinDepartment of Gastrointestinal Surgery, Jiangmen Central Hospital, Jiangmen, China.
Yu HeNational Drug Clinical Trial Institution, Jiangmen Central Hospital, Jiangmen, China.
Meimei WuClinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Jiangmen, China.
Zijie MengClinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Jiangmen, China.
Yuehua LiaoDepartment of Pathology, Jiangmen Central Hospital, Jiangmen, China.
Min LiThe First Affiliated Hospital, Jinan University, Guangzhou, China.
Mariya El AkkawiDepartment of Plastic and Aesthetic Surgery, Zhujiang hospital of Southern Medical University, Guangzhou, China.
Jinglin ZhaoDepartment of Gastrointestinal Surgery, Jiangmen Central Hospital, Jiangmen, China.
Yaoming HeDepartment of Gastrointestinal Surgery, Jiangmen Central Hospital, Jiangmen, China.
Jiangmen Central Hospital · CNZhujiang Hospital · CNFirst Affiliated Hospital of Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CUL7, a gene composed of 26 exons associated with cullin 7 protein, is also an E3 ligase that is closely related to cell senescence, apoptosis, and cell transformation and also plays an important role in human cancer. However, there is no systematic pan-cancer analysis has been performed to explore its role in prognosis and immune prediction. In this study, the expression of CUL7 in colon adenocarcinoma (COAD) was investigated to determine its prognosis value. First, based on the Cancer Genome Atlas (TCGA), Genotypic-Tissue Expression Project(GTEx), Cancer Cell Line Encyclopedias(CCLE), and TISIDB database, the potential role of CUL7 in different tumors was explored. Subsequently, the expression of CUL7 in COAD was explored and verified by Immunohistochemistry (IHC). Furthermore, the mutation frequency of CUL7 in COAD was analyzed, and the prognostic value of CUL7 in COAD was discussed. In addition, the nomogram was constructed, and its prognostic value was verified by follow-up data from Jiangmen Central Hospital. Finally, PPI network analysis explored the potential biological function of CUL7 in COAD. The results show that CUL7 is upregulated in most tumors, which is significantly associated with poor survival. At the same time, CUL7 is correlated with the clinical stage and immune landscape of various tumors. In colorectal cancer, CUL7 was overexpressed in tumor tissues by IHC with a mutation frequency of about 4%. CUL7 is an independent prognostic factor for colorectal cancer. The nomogram constructed has effective predictive performance, and external databases proved the prognostic value of CUL7. In addition, PPI network analysis showed that CUL7 was closely related to FBXW8, and further pathway enrichment analysis showed that CUL7 was mainly involved in ubiquitin-mediated proteolysis. Therefore, our study provides a comprehensive understanding of the potential role of CUL7 in different tumors, and CUL7 might be a prognostic marker for COAD.

Indexed as

AdenocarcinomaColonic NeoplasmsCullin ProteinsHumansNomogramsPrognosisCUL7 protein, humanCullin ProteinsCOADCUL7pan-cancerprognosistumor immunity

Identifiers

PMID36304472
PMCPMC9592904
OpenAlexW4304175284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.